Cancer patient symptom and physical function reporting by caregivers used as predictors of adverse clinical outcomes

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer

RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies

ASCO 2022: Testing and diagnostics in EGFR exon 20 insertion positive NSCLC

ASCO and WHO to collaborate on quality indicators for cancer facilities

Lack of access to new cancer medicines in LMICs

Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases

Spotlight on global cancer control at ASCO 2022

ASCO 2022: Head and neck cancer highlights

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Comment: Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy

Momelotinib superior to danazol in symptomatic and anaemic myelofibrosis patients previously treated with a JAK inhibitor

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients

ASCO 2022: Highlights and analysis

Pembrolizumab demonstrates clinically meaningful improvement in distant metastasis-free survival in patients with melanoma

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib

Pancreatic neuroendocrine tumours: Capecitabine plus temozolomide gives longer PFS than temozolomide alone

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Can we afford the cost of newly approved targeted therapeutics in the management of breast cancer globally?

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Comment: Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Avasopasem produces significant improvement of severe oral mucositis in head and neck patients

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

N-803-BCG combination shows promising results in BCG-unresponsive NMIBC

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

ASCO and WHO to collaborate on quality indicators for cancer facilities

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Ramucirumab plus pembrolizumab improves OS in advanced NSCLC

Ibrutinib plus chemoimmunotherapy improved PFS for newly diagnosed MCL